FRANKLIN, Tenn.--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today the appointment of Gary E. Friedlaender, M.D. to its board of directors. As the current co-chairman of BioMimetic’s Orthopedic Scientific Advisory Board, Dr. Friedlaender brings with him extensive knowledge of the Company and its pipeline of product candidates. He will begin fulfilling his role on the board effective immediately.
